IBDEI15F ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,18649,1,4,0)
;;=4^I50.810
;;^UTILITY(U,$J,358.3,18649,2)
;;=^5151384
;;^UTILITY(U,$J,358.3,18650,0)
;;=I50.811^^64^833^63
;;^UTILITY(U,$J,358.3,18650,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18650,1,3,0)
;;=3^Heart Failure,Right,Acute
;;^UTILITY(U,$J,358.3,18650,1,4,0)
;;=4^I50.811
;;^UTILITY(U,$J,358.3,18650,2)
;;=^5151385
;;^UTILITY(U,$J,358.3,18651,0)
;;=I50.812^^64^833^65
;;^UTILITY(U,$J,358.3,18651,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18651,1,3,0)
;;=3^Heart Failure,Right,Chronic
;;^UTILITY(U,$J,358.3,18651,1,4,0)
;;=4^I50.812
;;^UTILITY(U,$J,358.3,18651,2)
;;=^5151386
;;^UTILITY(U,$J,358.3,18652,0)
;;=I50.813^^64^833^64
;;^UTILITY(U,$J,358.3,18652,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18652,1,3,0)
;;=3^Heart Failure,Right,Acute on Chronic
;;^UTILITY(U,$J,358.3,18652,1,4,0)
;;=4^I50.813
;;^UTILITY(U,$J,358.3,18652,2)
;;=^5151387
;;^UTILITY(U,$J,358.3,18653,0)
;;=I21.A1^^64^833^72
;;^UTILITY(U,$J,358.3,18653,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18653,1,3,0)
;;=3^Myocardial Infarction,Type 2
;;^UTILITY(U,$J,358.3,18653,1,4,0)
;;=4^I21.A1
;;^UTILITY(U,$J,358.3,18653,2)
;;=^5151374
;;^UTILITY(U,$J,358.3,18654,0)
;;=I48.11^^64^833^46
;;^UTILITY(U,$J,358.3,18654,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18654,1,3,0)
;;=3^Atrial Fibrillation,Longstanding Persistent
;;^UTILITY(U,$J,358.3,18654,1,4,0)
;;=4^I48.11
;;^UTILITY(U,$J,358.3,18654,2)
;;=^5158046
;;^UTILITY(U,$J,358.3,18655,0)
;;=I48.19^^64^833^44
;;^UTILITY(U,$J,358.3,18655,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18655,1,3,0)
;;=3^Atrial Fibrillation,Chr Persistent
;;^UTILITY(U,$J,358.3,18655,1,4,0)
;;=4^I48.19
;;^UTILITY(U,$J,358.3,18655,2)
;;=^5158047
;;^UTILITY(U,$J,358.3,18656,0)
;;=I48.20^^64^833^45
;;^UTILITY(U,$J,358.3,18656,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18656,1,3,0)
;;=3^Atrial Fibrillation,Chr Unspec
;;^UTILITY(U,$J,358.3,18656,1,4,0)
;;=4^I48.20
;;^UTILITY(U,$J,358.3,18656,2)
;;=^5158048
;;^UTILITY(U,$J,358.3,18657,0)
;;=I48.21^^64^833^48
;;^UTILITY(U,$J,358.3,18657,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18657,1,3,0)
;;=3^Atrial Fibrillation,Permanent
;;^UTILITY(U,$J,358.3,18657,1,4,0)
;;=4^I48.21
;;^UTILITY(U,$J,358.3,18657,2)
;;=^304710
;;^UTILITY(U,$J,358.3,18658,0)
;;=Z79.82^^64^833^71
;;^UTILITY(U,$J,358.3,18658,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18658,1,3,0)
;;=3^Long Term (Current) Use of Aspirin
;;^UTILITY(U,$J,358.3,18658,1,4,0)
;;=4^Z79.82
;;^UTILITY(U,$J,358.3,18658,2)
;;=^5063340
;;^UTILITY(U,$J,358.3,18659,0)
;;=Z79.01^^64^833^69
;;^UTILITY(U,$J,358.3,18659,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18659,1,3,0)
;;=3^Long Term (Current) Use of Anticoagulants
;;^UTILITY(U,$J,358.3,18659,1,4,0)
;;=4^Z79.01
;;^UTILITY(U,$J,358.3,18659,2)
;;=^5063330
;;^UTILITY(U,$J,358.3,18660,0)
;;=Z79.02^^64^833^70
;;^UTILITY(U,$J,358.3,18660,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18660,1,3,0)
;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
;;^UTILITY(U,$J,358.3,18660,1,4,0)
;;=4^Z79.02
;;^UTILITY(U,$J,358.3,18660,2)
;;=^5063331
;;^UTILITY(U,$J,358.3,18661,0)
;;=E87.8^^64^834^12
;;^UTILITY(U,$J,358.3,18661,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18661,1,3,0)
;;=3^Electrolyte/Fluid Balance Disorders NEC
;;^UTILITY(U,$J,358.3,18661,1,4,0)
;;=4^E87.8
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI15F 3769 printed Sep 23, 2025@19:38:07 Page 2
IBDEI15F ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,18649,1,4,0)
+2 ;;=4^I50.810
+3 ;;^UTILITY(U,$J,358.3,18649,2)
+4 ;;=^5151384
+5 ;;^UTILITY(U,$J,358.3,18650,0)
+6 ;;=I50.811^^64^833^63
+7 ;;^UTILITY(U,$J,358.3,18650,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,18650,1,3,0)
+10 ;;=3^Heart Failure,Right,Acute
+11 ;;^UTILITY(U,$J,358.3,18650,1,4,0)
+12 ;;=4^I50.811
+13 ;;^UTILITY(U,$J,358.3,18650,2)
+14 ;;=^5151385
+15 ;;^UTILITY(U,$J,358.3,18651,0)
+16 ;;=I50.812^^64^833^65
+17 ;;^UTILITY(U,$J,358.3,18651,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,18651,1,3,0)
+20 ;;=3^Heart Failure,Right,Chronic
+21 ;;^UTILITY(U,$J,358.3,18651,1,4,0)
+22 ;;=4^I50.812
+23 ;;^UTILITY(U,$J,358.3,18651,2)
+24 ;;=^5151386
+25 ;;^UTILITY(U,$J,358.3,18652,0)
+26 ;;=I50.813^^64^833^64
+27 ;;^UTILITY(U,$J,358.3,18652,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,18652,1,3,0)
+30 ;;=3^Heart Failure,Right,Acute on Chronic
+31 ;;^UTILITY(U,$J,358.3,18652,1,4,0)
+32 ;;=4^I50.813
+33 ;;^UTILITY(U,$J,358.3,18652,2)
+34 ;;=^5151387
+35 ;;^UTILITY(U,$J,358.3,18653,0)
+36 ;;=I21.A1^^64^833^72
+37 ;;^UTILITY(U,$J,358.3,18653,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,18653,1,3,0)
+40 ;;=3^Myocardial Infarction,Type 2
+41 ;;^UTILITY(U,$J,358.3,18653,1,4,0)
+42 ;;=4^I21.A1
+43 ;;^UTILITY(U,$J,358.3,18653,2)
+44 ;;=^5151374
+45 ;;^UTILITY(U,$J,358.3,18654,0)
+46 ;;=I48.11^^64^833^46
+47 ;;^UTILITY(U,$J,358.3,18654,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,18654,1,3,0)
+50 ;;=3^Atrial Fibrillation,Longstanding Persistent
+51 ;;^UTILITY(U,$J,358.3,18654,1,4,0)
+52 ;;=4^I48.11
+53 ;;^UTILITY(U,$J,358.3,18654,2)
+54 ;;=^5158046
+55 ;;^UTILITY(U,$J,358.3,18655,0)
+56 ;;=I48.19^^64^833^44
+57 ;;^UTILITY(U,$J,358.3,18655,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,18655,1,3,0)
+60 ;;=3^Atrial Fibrillation,Chr Persistent
+61 ;;^UTILITY(U,$J,358.3,18655,1,4,0)
+62 ;;=4^I48.19
+63 ;;^UTILITY(U,$J,358.3,18655,2)
+64 ;;=^5158047
+65 ;;^UTILITY(U,$J,358.3,18656,0)
+66 ;;=I48.20^^64^833^45
+67 ;;^UTILITY(U,$J,358.3,18656,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,18656,1,3,0)
+70 ;;=3^Atrial Fibrillation,Chr Unspec
+71 ;;^UTILITY(U,$J,358.3,18656,1,4,0)
+72 ;;=4^I48.20
+73 ;;^UTILITY(U,$J,358.3,18656,2)
+74 ;;=^5158048
+75 ;;^UTILITY(U,$J,358.3,18657,0)
+76 ;;=I48.21^^64^833^48
+77 ;;^UTILITY(U,$J,358.3,18657,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,18657,1,3,0)
+80 ;;=3^Atrial Fibrillation,Permanent
+81 ;;^UTILITY(U,$J,358.3,18657,1,4,0)
+82 ;;=4^I48.21
+83 ;;^UTILITY(U,$J,358.3,18657,2)
+84 ;;=^304710
+85 ;;^UTILITY(U,$J,358.3,18658,0)
+86 ;;=Z79.82^^64^833^71
+87 ;;^UTILITY(U,$J,358.3,18658,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,18658,1,3,0)
+90 ;;=3^Long Term (Current) Use of Aspirin
+91 ;;^UTILITY(U,$J,358.3,18658,1,4,0)
+92 ;;=4^Z79.82
+93 ;;^UTILITY(U,$J,358.3,18658,2)
+94 ;;=^5063340
+95 ;;^UTILITY(U,$J,358.3,18659,0)
+96 ;;=Z79.01^^64^833^69
+97 ;;^UTILITY(U,$J,358.3,18659,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,18659,1,3,0)
+100 ;;=3^Long Term (Current) Use of Anticoagulants
+101 ;;^UTILITY(U,$J,358.3,18659,1,4,0)
+102 ;;=4^Z79.01
+103 ;;^UTILITY(U,$J,358.3,18659,2)
+104 ;;=^5063330
+105 ;;^UTILITY(U,$J,358.3,18660,0)
+106 ;;=Z79.02^^64^833^70
+107 ;;^UTILITY(U,$J,358.3,18660,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,18660,1,3,0)
+110 ;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
+111 ;;^UTILITY(U,$J,358.3,18660,1,4,0)
+112 ;;=4^Z79.02
+113 ;;^UTILITY(U,$J,358.3,18660,2)
+114 ;;=^5063331
+115 ;;^UTILITY(U,$J,358.3,18661,0)
+116 ;;=E87.8^^64^834^12
+117 ;;^UTILITY(U,$J,358.3,18661,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,18661,1,3,0)
+120 ;;=3^Electrolyte/Fluid Balance Disorders NEC
+121 ;;^UTILITY(U,$J,358.3,18661,1,4,0)
+122 ;;=4^E87.8
